Abstract Decisions in drug development are made based upon determinations of cause and effect from experimental observations that span all development phases. Despite major advances in our powers of observation due to the advent of multi-omic technologies, the ability to determine disease mechanisms, biomarkers, and effective combination therapies from large-scale and diverse data sets in the context of ill-defined and complex biological systems continues to be a major bottleneck in the drug development process. Current methods of statistical analysis do not allow for causal inferences, leaving this impossible task to the human mind. This major bottleneck can only be overcome by utilizing automated computational learning methods that identify from compound data the circuits and connections between drug-affected molecular constituents and physiological observables. We will present several case studies in oncology drug development where we employ massively parallel machines to reverse engineer populations of models that predict the ‘gearing’ between drug, genetic, and genomic molecular components with respect to oncology phenotypic outcomes. Since a single topology or model cannot capture the reality of a biological system under investigation, Monte Carlo simulation strategies over the population of models reveal how the drug, genetic, gene expression and clinical variables work together to impact phenotypic outcomes. We will show how the marriage of multi-omic technologies within the network inference approach is helping to fill in the missing insights needed to improve drug development success rates. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr SY14-03. doi:10.1158/1538-7445.AM2011-SY14-03
Read full abstract